Format

Send to

Choose Destination
Int J Neuropsychopharmacol. 2012 Apr;15(3):403-15. doi: 10.1017/S1461145711000800. Epub 2011 Jun 9.

Evidence-based pharmacotherapy of panic disorder: an update.

Author information

1
Department of Psychiatry and EMGO Institute, VU University Medical Center Amsterdam and GGZ inGeest, Amsterdam, The Netherlands.
2
University of Stellenbosch, Cape Town, South Africa.

Abstract

The evidence-based pharmacotherapy of panic disorder continues to evolve. This paper reviews data on first-line pharmacotherapy, evidence for maintenance treatment, and management options for treatment-refractory patients. A Medline search of research on pharmacotherapy was undertaken, and a previous systematic review on the evidence-based pharmacotherapy of panic disorder was updated. Selective serotonin reuptake inhibitors remain a first-line pharmacotherapy of panic disorder, with the serotonin noradrenaline reuptake inhibitor venlafaxine also an acceptable early option. Temporary co-administration of benzodiazepines can be considered. Maintenance treatment reduces relapse rates, but further research to determine optimal duration is needed. For patients not responding to first-line agents several pharmacotherapy options are available, but there is a notable paucity of data on the optimal choice.

PMID:
21733234
DOI:
10.1017/S1461145711000800
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center